

Melatonin: More Than Just the Hormone That Regulates Sleep

Copyright: Pamela W. Smith, MD, MPH, MS

Complete References

1. Smith, S., *What You Must Know About Women's Hormones*. Garden City Park, NY: Square One Publishers, 2010.
2. Reiter, R., "Melatonin: clinical relevance," *Best Pract Res Clin Endocrinol Metab* 2003; 17(2):273-85.
3. Sinatra, S., "Melatonin shows promise against age-related disorders," *Heart Health and Nutrition* 2007; 13(9):6-7
4. Tan, D., et al., "Melatonin: a potent endogenous hydroxyl radical scavenger," *Endocrin Jour* 1993; 1:57-60.
5. Tordjman, S., et al., "Melatonin: pharmacology, functions and therapeutic benefits," *Curr Neuropharmacol* 2017; 15(3):434-43.
6. Arangino, S., et al., "Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men," *Amer Jour Cardiol* 1999; 83:1417.
7. Scheer, F., et al., "Daily night-time melatonin reduces blood pressure in male patients with essential hypertension," *Hypertension* 2004; 43:192-97.
8. Grossman, E., et al., "Melatonin reduces night blood pressure in patients with nocturnal hypertension," *Amer Jour Med* 2006; 119(10):898-902.
9. Dominguez-Rodriguez, A., et al., "Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation my in myocardial infarction," *Amer Jour Cardiol* 2006; 97(8):1162-64.
10. Dominguez-Rodriguez, A., et al., "Melatonin and circadian biology in human cardiovascular disease," *Jour Pineal Res* 2010; 49(1):14-22.
11. Reiter, R., et al., "Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart," *Cardiovasc Res* 2003; 58(1):10-9.



Melatonin - COMPLETE REFERENCES

12. Dominguez-Rodriguez, A., et al., "Clinical aspects of melatonin in the acute coronary syndrome," *Curr Vasc Pharmacol* 2009; 7(3):367-73.
13. Dominguez-Rodriguez, A., et al., "Relation of nocturnal melatonin levels to c-reactive protein concentration in patients with T-segment elevation myocardial infarction," *Amer Jour Cardiol* 2006; 91(1):10-2.
14. Xu, M., et al., "Melatonin protection against lethal myocyte injury induced by doxorubicin as reflected by effects on mitochondrial membrane potential," *Jour Mol Cell Cardiol* 2003; 34(1):75-9.
15. Cipolla-Neto, J., et al., "Melatonin, energy metabolism, and obesity: a review," *Jour Pineal Res* 2014; 56(4):371-81.
16. Wolden-Hanson, T., et al., "Daily melatonin administration to middle-aged rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin: independent of food intake and total body fat," *Endocrinology* 2000; 141(2):487-97.
17. Pandi-Perumal, S., et al., "Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes," *Neurotox Res* 2013; 23(3):267-300.
18. Gupta, Y., et al., "Neuroprotective role of melatonin in oxidative stress vulnerable brain," *Indian Jour Physiol Pharmacol* 2003; 47(4):373-86.
19. Bondy, S., et al., "Retardation of brain aging by chronic treatment with melatonin," *Ann NY Acad Sci* 2004; 1035:197-215.
20. Lahiri, D., et al., "Melatonin, metals, and gene expression: implications in aging and neurodegenerative disorders," *Ann NY Acad Sci* 2004; 1035:216-30.
21. De Rooij, S., et al., "Melatonin deficiency hypothesis in delirium. A synthesis of current evidence," *Rejuvenation Res* 2013; April 13.
22. Fredericks, S., "Melatonin: The brain hormone," *Life Extension*, Sep 2013, p. 40-9.
23. Liu, R., et al., "Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging," Alzheimer's disease, and apolipoprotein E-epsilon 4/4 genotype," *Jour Clin Endocrinol Metab* 1999; 84(1):323-27.
24. *Ibid.*, Pandi-Perumal.
25. *Ibid.*, Lahiri.
26. Ma, J., et al., "Does melatonin help save dopaminergic cells in MPTP-treated mice?" *Parkinsonism Relat Disord* 2009; 15(4):307-14.
27. Borah, A., et al., "Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents," *Jour Pineal Res* 2009; 47(4):293-300.

Melatonin - COMPLETE REFERENCES

28. Reiter, R., et al., "Melatonin ameliorates neurologic damage and neurologic damage and neurophysiologic deficits in experimental models of stroke," *Ann NY Acad Sci* 2003; 993:35-47.
29. Bondy, S., et al., "Retardation of brain aging by chronic treatment with melatonin," *Ann NY Acad Sci* 2004; 1035:197-215.
30. Feng, Z., et al., "Early melatonin supplementation alleviates oxidative stress in a transgenic-mouse model of Alzheimer's disease," *Free Radic Biol Med* 2006; 40(1):101-09.
31. Cardinali, D., et al., "The use of melatonin in Alzheimer's disease," *Neuro Endocrinol Lett* 2002; 23(Suppl 1):20-3.
32. Cardinali, D., et al., "The use of chronobiotics in the synchronization of the sleep/wake cycle. Therapeutic application in the early phases of Alzheimer's disease," *Recent Pat Endocr Metab Immune Drug Discov* 2011; 5(2):80-90.
33. Feng, Z., et al., "Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic-mouse model of Alzheimer's disease," *Jour Pineal Res* 2004; 37(2):129-36.
34. Wang, J., et al., "Role of melatonin in Alzheimer-like neurodegeneration," *Acta Pharmacol* 2006; 27(1):41-9.
35. Zhu, L., et al., "Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat," *Jour Pineal Res* 2004; 37(2):71-7.
36. Daniels, W., et al., "Melatonin prevents beta-amyloid-induced lipid peroxidation," *Jour Pineal Res* 1998; 24(2):78-82.
37. Lahiri, D., et al., "Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in murine cerebral cortex," *Jour Pineal Res* 2004; 36(4):224-31.
38. Feng, Z., et al., "Early melatonin supplementation alleviates oxidative stress in a transgenic-mouse model of Alzheimer's disease," *Free Radic Biol Med* 2006; 40(1):101-09.
39. Cardinali, D., et al., "Clinical aspects of melatonin intervention in Alzheimer's disease progression," *Curr Neuropharmacol* 2010; 8(3):218-27.
40. *Ibid.*, Daniels.
41. Lahiri, D., et al., "Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases," *Ann NY Acad Sci* 2005; 1056:430-49.
42. Cardinali, D., et al., "Therapeutic application of melatonin in mild cognitive impairment," *Amer Jour Neurodegener Dis* 2012; 1(3):280-91.
43. *Ibid.*, Fredericks
44. *Ibid.*, Cardinali, 2010.

Melatonin - COMPLETE REFERENCES

45. Cardinali, D., et al., "Therapeutic application of melatonin in mild cognitive impairment," *Amer Jour Neurodegener Dis* 2012; 1(3):280-91.
46. Furio, A., et al., "Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study," *Jour Pineal Res* 2007; 43(4):404-09.
47. Chang, H., et al., "Melatonin preserves longevity protein (sirtuin 1): expression in the hippocampus of total sleep-deprived rats," *Jour Pineal Res* 2009; 47(3):211-20.
48. Ayer, R., et al., "Effects of melatonin in early brain injury following subarachnoid hemorrhage," *Actu Neurochir Suppl* 2008; 102:327-30.
49. *Ibid.*, Wang.
50. *Ibid.*, Pandi-Perumal.
51. Patki, G., et al., "Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease," *Pharmacol Biochem Behav* 2011; 99(4):704-11.
52. Gutierrez-Valdez, A., et al., "Effects of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis," *ISRN Neurol* 2012; 2012:360379.
53. *Ibid.*, Ma.
54. Ono, K., et al., "Effect of melatonin on alpha-synuclein self-assembly and cytotoxicity," *Neurobiol Aging* 2012; 33(9):2172-85.
55. *Ibid.*, Ono.
56. Sae-Ung, K., et al., "Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats," *Jour Pineal Res* 2012; 52(1):128-37.
57. Brito-Armas, J., et al., "Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing A30P mutant alpha-synuclein," *Histol Histopathol* 2013; Feb 27.
58. Niranjana, R., et al., "The mechanism of action of MPTO-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells," *C6 Free Radic Res* 2010; 44(11):1304-16.
59. *Ibid.*, Cardinali, 2002.
60. *Ibid.*, Niranjana.
61. *Ibid.*, Ma.
62. *Ibid.*, Borah.

Melatonin - COMPLETE REFERENCES

63. Atanassova, P., et al., "Impaired nocturnal melatonin in acute phase of ischaemic stroke: cross-sectional matched case-control analysis," *Jour Neuroendocrinol* 2009; 21(7):657-63.
64. Kitkhuandee, A., et al., "Pineal calcification is associated with symptomatic cerebral infarction," *Jour Stroke Cerebrovasc Dis* 2013; Feb. 20.
65. *Ibid.*, Pandi-Perumal.
66. *Ibid.*, Lahiri.
67. *Ibid.*, Feng.
68. *Ibid.*, Niranjana.
69. *Ibid.*, Ma.
70. Deykun, K., et al., "Modulations of behavioral consequences of minor cortical ischemic lesion by application of free radical scavengers," *Gen Physiol Biophys* 2011; 30(3):263-70.
71. Sewerynek, E., et al., "Melatonin and the cardiovascular system," *Neuro Endocrinol Lett* 2002; 23(Supp 1):79-83.
72. Maney, H., et al., "Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats," *FASEB Jour* 1996; 10(13):1546-51.
73. Chen, H., et al., "Melatonin improves presynaptic protein, SNAP-25, expression and dendritic spin density and enhances functional and electrophysiological recovery following transient focal cerebral ischemia in rats," *Jour Pineal Res* 2009; 47(3):260-70.
74. Hung, Y., et al., "Melatonin decreases matrix metalloproteinase-9 activation and expression and attenuates reperfusion-induced hemorrhage following transient focal cerebral ischemia in rats," *Jour Pineal Res* 2008; 45(4):459-67.
75. Jang, J., et al., "Melatonin reduced the elevated matrix metalloproteinase-9 level in a rat photothrombotic stroke model," *Jour Neuro Sci* 2012; 15:323(1-2):221-27.
76. *Ibid.*, Reiter.
77. *Ibid.*, Hung.
78. *Ibid.*, Jang.
79. Reiter, R., et al., "When melatonin gets on your nerves: its beneficial actions in experimental models of stroke," *Exp Biol Med (Maywood)* 2005; 230(2):104-17.
80. *Ibid.*, Pandi-Perumal.
81. *Ibid.*, Feng.
82. *Ibid.*, Ma.

Melatonin - COMPLETE REFERENCES

83. **Ibid., Reiter.**
84. **Ibid., Niranjan.**
85. **Ibid., Lahiri.**
86. **Tsai, M., et al., "Melatonin attenuates brain contusion-induced oxidative insult, inactivation of signal transducers and activators of transcription 1, and up-regulation of suppressor of cytokine signalin-3 in rats," Jour Pineal Res 2011; 51(2):233-45.**
87. **Ismailoglu, O., et al., "The therapeutic effects of melatonin and nimodipine in rats after cerebral cortical injury," Turk Neurosurg 2012; 22(6):740-46.**
88. **Ibid., Ismailoglu.**
89. **Ayer, R., et al., "Effects of melatonin in early brain injury following subarachnoid hemorrhage," Acta Neurochir Suppl 2008; 102:327-30.**
90. **Ibid., Wang.**
91. **Xie, Z., et al., "A review of sleep disorders and melatonin," Neurol Res 2017; 29(6):559-65.**
92. **Auld, F., et al., "Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders," Sleep Med Rev 2017; 34:10-22.**
93. **Hansen, M., et al., "Melatonin for pre-and postoperative anxiety in adults," Cochrane Database Syst Rev 2015; 2015(4):CD009861.**
94. **Zhang, R., et al., "COVID-19: Melatonin as a potential adjuvant treatment," Life Sci 2020; 250:117583.**
95. **Salles, C., et al., "Correspondence COVID-19: Melatonin as a potential adjuvant treatment," Life Sci 2020; 253:117716.**
96. **Juybari, K., et al., "Melatonin potentials against viral infections including COVID-19: Current evidence and new findings," Vires Res 2020; 287:198108.**
97. **El-Missiry, M., et al., "Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of COVID-19," Eur Jour Pharmacol 2020; 882:173329.**
98. **Barcelo, S., et al., "Breast cancer therapy based on melatonin," Recent Pat Endocr Metab Immune Drug Discov 2012; 6(2):108-16.**
99. **Cos, S., et al., "Melatonin as a selective estrogen enzyme modulator," Curr Cancer Curr Cancer Drug Targets 2008; 8(8):691-702.**
100. **Proietti, S., et al., "Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFB-1-dependent growth inhibition of breast cancer cells," Jour Pineal Res 2011; 50(2):150-58.**

Melatonin - COMPLETE REFERENCES

101. **Thaiz-Ferraz, B., et al., “Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression,” Jour Pineal Res 2015; Aug. 21.**
102. **do Nascimento Goncalves, N., et al., “Effect of melatonin in epithelial mesenchymal transition markers and invasive properties of breast cancer stem cells of canine and human cell lines,” PLoS One 2016; 11(3):e0150407.**
103. **Sanchez-Barcelo, E., et al., “Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation,” Expert Opin Investig Drugs 2012; 21(6):819-31.**
104. **Mills, E., et al., “Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis,” Jour Pineal Res 2005; 39(4):360-66.**
105. **Csaba, G., “The pineal regulation of the immune system: 40 years since the discovery,” Acta Microbiol Immunol Hung, 2013; 60(2):77-91.**
106. **Bondy, S., et al., “Melatonin and regulation of immune function: Impact on numerous diseases,” Curr Aging Sci 2020; Jul 11. doi: 10.2174/1874609813666200711153223, on-line ahead of print.**
107. **Esteban-Zubero, E., et al., “Melatonin’s role as a co-adjuvant treatment in colonic disease: A review,” Life Sci 2017; 170:72-81.**
108. **Konturek, S., et al., “Role of melatonin in upper gastrointestinal tract,” Jour Physiol Pharmacol 2007; 58(Suppl 6):23-52.**
109. **Konturek, S., et al., “Localization and biological activities of melatonin in intact and diseased gastrointestinal tract (GIT),” Jour Physiol Pharmacol 2007; 58(3):381-405.**
110. **de Souza Pereira, R., “Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and amino acids: comparison with omeprazole,” Jour Pineal Res 2006; 41:195–200.**
111. **Kandil, T., et al., “The potential therapeutic effect of melatonin in gastroesophageal reflux disease,” BMC Gastroenterol 2010; 10:7.**
112. **Werbach, M., “Melatonin for the treatment of gastroesophageal reflux disease,” Altern Ther Health Med 2008, 14(4):54–8.**
113. **Bubenik, G., et al., “Localization, physiological significance and possible clinical implication of gastrointestinal melatonin,” Biol Signals Recept 2001; 10(6):350-66.**
114. **Brzozowska, J., et al., “Mucosal strengthening activity of central and peripheral melatonin in the mechanism of gastric defense,” Jour Physiol Pharmacol 2009; 60(Suppl 7):47-56.**
115. **Brzozowski, T., et al., “Importance of the pineal gland, endogenous prostaglandins and sensory nerves in the gastroprotective actions of central and peripheral melatonin against stress-induced damage,” Jour Pineal Res 2005; 39(4):375-85.**

Melatonin - COMPLETE REFERENCES

116. Brzozowska, I., et al., "Mechanisms of esophageal protection, gastroprotection and ulcer healing by melatonin. Implications for the therapeutic use of melatonin in gastroesophageal reflux disease (GERD) and peptic ulcer disease," *Curr Pharm Des* 2014; 20(30):4807-15.
117. Brzozowski, T., et al., "Role of circadian rhythm and endogenous melatonin in pathogenesis of acute gastric bleeding erosions induced by stress," *Jour Physiol Pharmacol* 2007; 58(Suppl 6):53-64.
118. Thor, P., et al., "Melatonin and serotonin effects on gastrointestinal motility," *Jour Physiol Pharmacol* 2007; 58(Suppl 6):97-103.
119. *Ibid.*, Esteban-Zubero.
120. Bubenik, G., "Thirty-four years since the discovery of gastrointestinal melatonin," *Jour Physiol Pharmacol* 2008; 59(Suppl 2):33-51.
121. Siah, K., et al., "Melatonin for the treatment of irritable bowel syndrome," *World Jour Gastroenterol* 2014; 20(10):2492-98.
122. Duboc, H., et al., "Disruption of circadian rhythms and gut motility: An overview of underlying mechanisms and associated pathologies," *Jour Clin Gastroenterol* 2020; 54(5):405-14.
123. Franch, P., et al., "Circadian rhythms in the pathogenesis of gastrointestinal diseases," *World Jour Gastroenterol* 2018; 24(38):4297-303.
124. Konturck, P., et al., "Gut clock: implication of circadian rhythms in the gastrointestinal tract," *Jour Physiol Pharmacol* 2011; 62(2):139-50.
125. Fatima, N., et al., "Metabolic implications of circadian disruption," *Pflugers Arch* 2020; 472(5):513-26.
126. Kim, S., et al., "Melatonin controls microbiota in colitis by goblet cell differentiation and antimicrobial peptide production through Toll-like receptor 4 signalling," *Sci Rep* 2020; 10:2232.
127. Bonomini, F., et al., "Dietary melatonin supplementation could be a promising preventing/therapeutic approach for a variety of liver diseases," *Nutrients* 2018; 10(9):1135.
128. Pierce, M., et al., "Optimal melatonin dose in older adults: A clinical review of the literature," *Sr Care Pharm* 2019; 34(7):419-31.
129. Viral, E., et al., "Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature," *Drugs Aging* 2014; 31(6):441-51.
130. Gooneratne, N., et al., "Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults," *Jour Pineal Res* 2012; 52(4):437-5.
131. Reiter, R., et al., "Therapeutic algorithm for use of melatonin in patients with COVID-19," *Front Med (Lausanne)* 2020; 7:226.
132. *Ibid.*, Reiter.